8:00 am Check-In, Badge Collection & Morning Coffee
8:50 am Chair’s Opening Remarks
Building a Consensus on Modeling Protocols to Empower Translation to the Clinic
9:00 am Syngeneic Models to Support Bispecific T Cell Engager Drug Development
Synopsis
- Model development to recapitulate the target expression and the tumor microenvironment
- Uncovering strategies for combination treatments
- Understanding mechanisms of treatment resistance
9:30 am Session Reserved for Certis Oncology
Synopsis
- Presentation details to be announced
10:00 am Generation & Characterization of a Post-Checkpoint Inhibitor Mouse Tumor Model of Resistance
Synopsis
- Mouse models that mimic the patient population in the clinic who have acquired resistance to checkpoint therapies
- Combination efficacy of our clinical assets in the IO refractory tumor models
- Leveraging these findings to improve translation to benefit Post-CPI patients
10:30 am Session Reserved for Champions Oncology
Synopsis
- Presentation details to be announced
11:00 am Morning Break & Speed Networking
Synopsis
As the tumor modeling community comes together once again, this session offers the perfect opportunity to reconnect with peers and forge new connections. Through a series of structured 3-5 minutes introductions, you'll be paired with fellow attendees, making it easy to expand your network and engage with industry colleagues!
Applications in Drug Discovery
& Screening
& Screening
11:45 am Adaptable & Hemodynamic Human Endothelial Cells for Immunotherapeutic Organoid Tumor Targeting
Synopsis
- Exploring the integration of multiple cell types, including immune cells and stromal cells, to create more physiologically relevant models
- Discussing how this device can be implemented for drug screening purposes and to uncover the molecular basis of tumor resistance and metastasis
- Showcasing a case study illustrating how this device provided critical insights into CAR-T development, and potential combination strategies
12:15 pm Session Reserved for DRL
Synopsis
- Presentation details to be announced
12:45 pm Lunch Hosted by Element Biosciences
Synopsis
Invite only networking lunch with experts from Element Biosciences
Applications for Efficacy Evaluation & Biomarker Discovery
Synopsis
Track Moderator: Hongyu Xue, Director, In Vivo Pharmacology, Oncology Research, Bayer
11:45 am Mastermind Session:Discussing the Different in vitro, in vivo, ex vivo & in silico Models in Use
Synopsis
- What models do you use, and in what context do you use them for?
- What challenges have you encountered, and how have you overcome them?
- What is the optimal number of preclinical models to accurately predict response in the clinic?
12:15 pm Session Reserved for Labcorp
Synopsis
- Presentation details to be announced
12:45 pm Lunch Break & Networking
1:45 pm Advancing Targeted Protein Degrader Identification Through Mathematical Models
Synopsis
- Spotlighting the development and use of mathematical models and theories to empower targeted protein degradation development
- Clarifying the interplay between different parameters responsible for modulating the pharmacodynamics response of TPDs
- Discussing the findings from these models and theories to gain a deep and intuitive understanding of the mechanism by which PROTACs and glue binders induce targeted protein degradation
2:15 pm Genetically Engineered Mouse Models to Empower Diffuse Large B Cell Lymphoma Therapeutic Improvement
Synopsis
- Whole exome sequencing in patients informs the generation of faithful mouse models to study DLBCL development and progression
- Single cell RNA sequencing allows to study B-cell lymphomagenesis and the concomitant T-cell-mediated immune response
- The combined analysis of asymptomatic animals at multiple time points and mice with lymphoma informs potential therapies for patients
1:45 pm Selection & Characterization of in vivo Models to Empower ADC Development & Decision-Making
Synopsis
- Discussing the challenges in choosing the right in vivo model that expresses the target of interest and matches the genetic profiles observed in the patient population
- Highlighting the rationale behind selecting the right cell-derived or patient-derived model
- Leveraging findings from models to inform decision-making
2:15 pm Advancing Cell Therapies Through Diverse Tumor Models
Synopsis
- Challenges in evaluating allogeneic cell therapies preclinically
- Rationale of selecting different tumor models to assess allogeneic cell therapies
- Assessing strategies to improve infiltration and persistence in tumor microenvironment
2:45 pm Afternoon Networking Break & Refreshments
Employing Clinical Lessons Learned & Pitting Subcutaneous Against Orthotopic Models to Uncover Translational Relevance
3:15 pm Smarter Models, Faster Approval: Leveraging Mouse Clinical Trials to Accelerate Drug Development
Synopsis
- Further presentation details to be announced
3:45 pm Patient-Derived Tumor Spheroids to Model the Tumor Microenvironment & Accelerate Drug Development
Synopsis
- Applying patient-derived tumor spheroids to model the tumor immune microenvironment including T cell infiltration and function, tumor fibrosis, CAF and endothelial cell biology
- Modeling the specific treatment response of compounds on the patient tumor immune environment and cancer epithelial cells using single cell RNASeq and proteomics
- Understanding how patient-derived tumor spheroids accelerate drug development using liver and pancreatic cancer as examples
4:15 pm Novel Applications of Humanized Mouse Models in Immuno-Oncology: Drug Evaluation & Target Identification Methods
Synopsis
- Using primed immune cells with cancer cells in co-inoculated models to overcome GVHD issues
- In vivo efficacy testing using fresh patient samples to best recapitulate the tumor microenvironment
- Target identification leveraging CRC (conditional reprogrammed cells) with fast in-vivo validation
4:45 pm Enhancing the Clinical Relevance of Brain Tumor Research Through Orthotopic Mouse Models
Synopsis
- Reiterating the importance of using multiple models to get a holistic view on oncology research
- Comparing subcutaneous versus orthotopic models to understand which model better replicates the tumor microenvironment
- Exploring the predictive power of orthotopic models in evaluating therapeutic response to lead better translation to the clinic for glioblastoma and pediatric brain tumors